Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | PNMT | P11086 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28926913 | 0.98 | CA1 (0.43) | CA1CA2TRPA1TSHRPNMT | |
| SCHEMBL31135690 | 0.81 | CA1 (0.35) | CA1CA2TRPA1TSHRPNMT | |
| SCHEMBL21694388 | 0.80 | PRKCQ (0.36) | CA1CA2 | |
| SCHEMBL2860480 | 0.80 | CA1 (0.33) | CA1CA2 | |
| SCHEMBL4946855 | 0.76 | ESR2 (0.33) | CA1CA2TSHRPNMTKDM4E | |
| SCHEMBL28067215 | 0.72 | PARP1 (0.43) | CA1CA2TRPA1TSHRPNMT | |
| SCHEMBL286500 | 0.72 | TRPA1 (0.33) | CA1CA2TRPA1TSHRPNMT | |
| SCHEMBL26606283 | 0.72 | CA1 (0.34) | CA1CA2KDM4EALDH1A1 | |
| SCHEMBL6454972 | 0.71 | CA1 (0.35) | CA1CA2TSHRALDH1A1HTR2C | |
| SCHEMBL11784140 | 0.71 | TRPA1 (0.45) | CA1CA2TRPA1TSHRGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174516-A1 | AMINO-PYRIMIDINE AMIDES | HOFFMANN-LA ROCHE INC. (US) | 2023-06-08 | — | — | US | claimed |
| EP-4161918-A1 | SUBSTITUTED AMINO-PYRIMIDINES | F. Hoffmann-La Roche AG (CH) | 2023-04-12 | — | — | EP | claimed |
| WO-2021249892-A1 | SUBSTITUTED AMINO-PYRIMIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2021-12-16 | — | — | WO | claimed |
| US-12077506-B2 | Indane derivatives as hypoxia inducible factor-2(α) inhibitors | NIKANG THERAPEUTICS, INC. (US) | 2024-09-03 | — | — | US | disclosed |
| US-20230167127-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-06-01 | — | — | US | disclosed |
| EP-4093509-A1 | SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2022-11-30 | — | — | EP | disclosed |
| US-20220306610-A1 | COMPOUNDS USEFUL FOR TREATING GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. (US) | 2022-09-29 | — | — | US | disclosed |
| WO-2021178780-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. (US) | 2021-09-10 | — | — | WO | disclosed |
| WO-2020081695-A1 | INDANE DERIVATIVES AS HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
| EP-3565808-A1 | COMPOUNDS USEFUL FOR TREATING GASTROINTESTINAL TRACT DISORDERS | Ardelyx, Inc. (US) | 2019-11-13 | — | — | EP | disclosed |
| CN-110256288-A | A method of preparing (S) -1- amino -2,3- dihydro -1H- indenes -4- formonitrile HCN | 苏州山青竹生物医药有限公司 | 2019-09-20 | — | — | CN | disclosed |
| WO-2018129552-A1 | COMPOUNDS USEFUL FOR TREATING GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. (US) | 2018-07-12 | — | — | WO | disclosed |
| CN-105061350-B | The sphingosine 1-phosphate receptor modulators and Chiral Synthesis of selectivity | 赛尔基因第二国际有限公司 | 2018-05-29 | — | — | CN | disclosed |
| CN-106470993-A | The azepine quinazoline inhibitor of Atypical protein kinase C | 癌症研究科技有限公司 | 2017-03-01 | — | — | CN | disclosed |
| EP-2632464-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2013-09-04 | — | — | EP | disclosed |
| EP-2632465-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2013-09-04 | — | — | EP | disclosed |
| WO-2012058116-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2012-05-03 | — | — | WO | disclosed |
| WO-2012058134-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2012-05-03 | — | — | WO | disclosed |
| EP-2427444-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2012-03-14 | — | — | EP | disclosed |
| EP-2291080-A1 | NOVEL MODULATORS OF SPHINGOSINE PHOSPHATE RECEPTORS | The Scripps Research Institute (US) | 2011-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220306610-A1 | COMPOUNDS USEFUL FOR TREATING GASTROINTESTINAL TRACT DISORDERS | SLC10A2, FABP2, SLC10A1 | CA1 3911/4885CA2 1499/4885TRPA1 419/4885 |
| US-12077506-B2 | Indane derivatives as hypoxia inducible factor-2(α) inhibitors | HIF1AN, HIF1A, NFE2L2 | CA1 1453/4885CA2 213/4885TRPA1 4086/4885 |
| US-20230167127-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | LTB4R, C5, C3AR1 | CA1 4207/4885CA2 2939/4885TRPA1 708/4885 |
| US-20230174516-A1 | AMINO-PYRIMIDINE AMIDES | TYMS, TYMP, DPYD | CA1 4389/4885CA2 4156/4885TRPA1 3037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.